Previous 10 | Next 10 |
Reverse split approved at April 2024 Special Meeting of Stockholders Shares of Jaguar Health common stock to begin trading on split-adjusted basis on May 23, 2024 SAN FRANCISCO, CA / ACCESSWIRE / May 17, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today anno...
2024-05-14 13:06:07 ET Jaguar Health, Inc. (JAGX) Q1 2024 Earnings Conference Call May 14, 2024, 08:30 AM ET Company Participants Lisa Conte - Founder, President and CEO Carol Lizak - CFO Conference Call Participants Presentation Operator ...
2024-05-14 09:14:57 ET More on Jaguar Health Jaguar Health, Inc. (JAGX) Q4 2023 Earnings Call Transcript Jaguar stock rallies 54% on licensing deal for chemo support drug Jaguar Health shareholders approve reverse stock split Seeking Alpha’s Quant Rati...
The combined net Q1 2024 revenue of approximately $2.4 million for prescription and non-prescription products increased approximately 20% versus net Q1 2023 revenue of $2.0 million and increased approximately 4% versus net Q4 2023 revenue of $2.3 million Top line results expected to be immin...
Click here to register for May 14 investor webcast Company plans to file its Earnings Report on May 14, 2024 on Form 10-Q for the quarter ended March 31, 2024 SAN FRANCISCO, CA / ACCESSWIRE / May 13, 2024 / Jaguar Health, Inc. ( NASDAQ:JAGX ) today issued a reminder that th...
2024-05-13 12:09:55 ET More on Jaguar Health Jaguar Health, Inc. (JAGX) Q4 2023 Earnings Call Transcript Jaguar stock rallies 54% on licensing deal for chemo support drug Jaguar Health shareholders approve reverse stock split Seeking Alpha’s Quant Rati...
A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) rose 20.3% to $0.0699 on volume of 164,902,840 shares Safe and Green Development Corporation (SGD) rose 36.7% to $0.8477 on volume of 100,466,382 shares PROSHARES TRUST (SQQQ) fell 0.6% to $1...
Jaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and SBS SAN FRANCISCO, CA / ACCESSWIRE / May 9, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Jaguar fam...
Click here to register for May 14 investor webcast Company plans to file its Earnings Report on May 14, 2024 on Form 10-Q for the quarter ended March 31, 2024 SAN FRANCISCO, CA / ACCESSWIRE / May 8, 2024 / Jaguar Health, Inc. ( NASDAQ:JAGX ) today announced that the company...
A look at the top 10 most actives in the United States XBP Europe Holdings Inc. (XBP) rose 69.1% to $3.5846 on volume of 37,660,870 shares Lyra Therapeutics Inc. (LYRA) fell 90.2% to $0.3942 on volume of 21,985,500 shares NIO Inc. American depositary shares each representing one Class A (...
News, Short Squeeze, Breakout and More Instantly...
Webcast on Tuesday, July 23rd at 8:30 AM Eastern will include updates on Jaguar's cancer supportive care portfolio, including participation from Jaguar scientific team, patient advocates, and leading oncology experts on cancer therapy-related diarrhea (CTD) and oral mucositis; Click here ...
New patents issued for core rare disease target indications for crofelemer Napo has approximately 200 patents issued and pending Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (...
Jaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July 23, 2024 Investor webcast on or before July 23 will include updates on Jaguar's cancer supportive care portfolio, including participation from Jaguar scientific ...